Richard E. Gilbert

MD, FRCPC, FRACP, FACP, FASN, PhD

Scientist, Keenan Research Centre for Biomedical Science

Biography

Richard Gilbert is Professor of Medicine at the University of Toronto, Canada Research Chair in Diabetes Complications and Head of the Division of Endocrinology at St. Michael’s Hospital in Toronto. His major interests are in the treatment and prevention of diabetic complications with an emphasis on nephropathy and heart failure. Dr. Gilbert has published over 220 peer-reviewed manuscripts, has numerous patents and co-founded Fibrotech, a biotechnology company that has brought novel anti-fibrotic therapies from the bench to early phase human trials. He is currently a member of the editorial board of Diabetes. Current research projects relate to the use of new therapies for the prevention and treatment of chronic kidney disease and heart failure. In addition to his bench research, Dr. Gilbert is actively involved in teaching and knowledge translation. He currently heads Guidelines Committees for the management of hypertension in diabetes.

Recent Publications

  1. Bami, K, Gandhi, S, Leong-Poi, H, Yan, AT, Ho, E, Zahrani, M et al.. Effects of Empagliflozin on Left Ventricular Remodeling in Patients with Type 2 Diabetes and Coronary Artery Disease: Echocardiographic Substudy of the EMPA-HEART CardioLink-6 Randomized Clinical Trial. J Am Soc Echocardiogr. 2020; :. doi: 10.1016/j.echo.2020.02.005. PubMed PMID:32199780 .
  2. Opingari, E, Verma, S, Connelly, KA, Mazer, CD, Teoh, H, Quan, A et al.. The impact of empagliflozin on kidney injury molecule-1: a subanalysis of the Effects of Empagliflozin on Cardiac Structure, Function, and Circulating Biomarkers in Patients with Type 2 Diabetes CardioLink-6 trial. Nephrol. Dial. Transplant. 2020; :. doi: 10.1093/ndt/gfz294. PubMed PMID:32159783 .
  3. Abrahamson, JR, Read, A, Chin, K, Mistry, N, Joo, H, Desjardins, JF et al.. Renal Tissue PO2 Sensing During Acute Hemodilution is Dependent on the Diluent. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2020; :. doi: 10.1152/ajpregu.00323.2019. PubMed PMID:32130021 .
  4. Connelly, KA, Zhang, Y, Desjardins, JF, Nghiem, L, Visram, A, Batchu, SN et al.. Load-independent effects of empagliflozin contribute to improved cardiac function in experimental heart failure with reduced ejection fraction. Cardiovasc Diabetol. 2020;19 (1):13. doi: 10.1186/s12933-020-0994-y. PubMed PMID:32035482 PubMed Central PMC7007658.
  5. Mazer, CD, Hare, GMT, Connelly, PW, Gilbert, RE, Shehata, N, Quan, A et al.. Effect of Empagliflozin on Erythropoietin Levels, Iron Stores, and Red Blood Cell Morphology in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease. Circulation. 2020;141 (8):704-707. doi: 10.1161/CIRCULATIONAHA.119.044235. PubMed PMID:31707794 .
  6. Gilbert, RE. Diabetic kidney disease 2.0: the treatment paradigm shifts. Lancet Diabetes Endocrinol. 2019;7 (11):820-821. doi: 10.1016/S2213-8587(19)30253-0. PubMed PMID:31495650 .
  7. Verma, S, Mazer, CD, Yan, AT, Mason, T, Garg, V, Teoh, H et al.. Effect of Empagliflozin on Left Ventricular Mass in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease: The EMPA-HEART CardioLink-6 Randomized Clinical Trial. Circulation. 2019;140 (21):1693-1702. doi: 10.1161/CIRCULATIONAHA.119.042375. PubMed PMID:31434508 .
  8. Bellin, AR, Zhang, Y, Thai, K, Rosenblum, ND, Cullen-McEwen, LA, Bertram, JF et al.. Impaired SIRT1 activity leads to diminution in glomerular endowment without accelerating age-associated GFR decline. Physiol Rep. 2019;7 (9):e14044. doi: 10.14814/phy2.14044. PubMed PMID:31087539 PubMed Central PMC6513772.
  9. Gilbert, RE, Thorpe, KE. Acute kidney injury with sodium-glucose co-transporter-2 inhibitors: A meta-analysis of cardiovascular outcome trials. Diabetes Obes Metab. 2019;21 (8):1996-2000. doi: 10.1111/dom.13754. PubMed PMID:31050116 .
  10. Connelly, KA, Zhang, Y, Visram, A, Advani, A, Batchu, SN, Desjardins, JF et al.. Empagliflozin Improves Diastolic Function in a Nondiabetic Rodent Model of Heart Failure With Preserved Ejection Fraction. JACC Basic Transl Sci. 2019;4 (1):27-37. doi: 10.1016/j.jacbts.2018.11.010. PubMed PMID:30847416 PubMed Central PMC6390677.
Search PubMed

Affiliations & Other Activities

  • Staff Physician, Department of Medicine, Division of Endocrinology, St. Michael’s Hospital
  • Professor, Department of Medicine, University of Toronto
X